Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00130507
Recruitment Status : Terminated (A new alternative treatment caused the decrease in the rhythm of recruitment.)
First Posted : August 15, 2005
Last Update Posted : February 26, 2019
Sponsor:
Collaborator:
Hoffmann-La Roche
Information provided by (Responsible Party):
Spanish Breast Cancer Research Group

Brief Summary:
Eligible patients must receive vinorelbine plus capecitabine, with or without trastuzumab, until disease progression or unbearable toxicity. Cycles will be administered every 3 weeks.Human epidermal growth factor receptor 2 (HER2) status must be locally assessed by immunohistochemistry (IHC). All 3+ patients are eligible. In 2+ patients, HER2 status must be confirmed by fluorescence in situ hybridization (FISH).

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Vinorelbine Drug: Capecitabine Drug: Trastuzumab Phase 2

Detailed Description:

Principal outcome is clinical benefit (complete + partial responses + stable disease). Sample size in each arm has been estimated with the Fleming method. Previous data show a clinical benefit rate of vinorelbine plus capecitabine around 50%. The researchers assume trastuzumab can increase it by 20%. With an alpha error of 0.05 and 80% power, 37 patients per arm are needed.

This is a randomised phase II trial. With a minimum expected benefit rate of 50%, at least 36 patients are needed to choose, with a 90% of probability to be right, the best treatment arm, providing it increases benefit rate at least by 15%.

Assuming a drop-out rate of 10%, the total number of patients needed is 82, 41 per treatment arm.

Patients will be stratified as per investigational site, and presence of visceral metastatic lesion (liver, lung, pleura, heart, peritoneum, suprarenal glands). All patients must receive 2 cycles. If no disease progression is detected, treatment must continue until progression or unbearable toxicity.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Trial to Assess the Benefit of Adding Trastuzumab to Capecitabine and Vinorelbine as Second Line for HER2positive Breast Cancer Patients With Locally Advanced or Metastatic Disease, Previously Treated With Trastuzumab and Taxanes
Actual Study Start Date : November 4, 2005
Actual Primary Completion Date : June 2009
Actual Study Completion Date : July 25, 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Active Comparator: Arm A: VX
Vinorelbine and capecitabine (VX): vinorelbine 25 mg/m2 iv, days 1 and 8 each cycle (21 days), followed of capecitabine 825 mg/m2, orally, twice a day, days 1-14 each cycle (21 days).
Drug: Vinorelbine
Other Name: Navelbine

Drug: Capecitabine
Other Name: Xeloda

Experimental: Arm B: VXH
Vinorelbine, capecitabine and trastuzumab (VXH): vinorelbine 25 mg/m2 iv, days 1 and 8 each cycle (21 days), followed of capecitabine 825 mg/m2, orally, twice a day, days 1-14 each cycle (21 days) and trastuzumab 4 mg/kg iv (loading dose first week), followed by 2 mg/kg weekly.
Drug: Vinorelbine
Other Name: Navelbine

Drug: Capecitabine
Other Name: Xeloda

Drug: Trastuzumab
Other Name: Herceptin




Primary Outcome Measures :
  1. Clinical benefit rate [ Time Frame: Through study completion, an average of 1 year ]
    Clinical benefit rate is defined as the rate of objective responses (complete responses and partial responses to treatment) and stabilizations, with a minimum duration of 24 weeks.


Secondary Outcome Measures :
  1. Time to progression (TTP) [ Time Frame: Through study completion, an average of 1 year ]
    Tumor assessments will be performed until disease progression in order to evaluate the TTP. TTP is defined as the time from the date of the first dose to the first date of objectively determined progressive disease. For patients not known to have objectively-determined progressive disease, TTP will be censored at the date of the last objective progression-free assessment. For patients who receive subsequent systemic anticancer therapy (after discontinuation from the study treatment) prior to objective disease progression, TTP will be censored at the date of last objective progression-free assessment prior to the initiation of postdiscontinuation systemic anticancer therapy.

  2. Objective Response Rate (ORR) [ Time Frame: Through study completion, an average of 1 year ]
    Tumor response will be assessed using RECIST criteria. The best response across all treatment will be recorded. ORR is defined as the percentage of patients with a complete or partial response out of the patients who had measurable disease at baseline.

  3. Response Duration (RD) [ Time Frame: Through study completion, an average of 1 year ]
    RD is defined as the time from the date when the measurement criteria are met for complete response (CR) or partial response (PR) (whichever status is recorded first) until the date of first observation of disease progression or death occurred. For responding patients not known to have died as of the data cut-off date and who do not have progression, duration of response will be censored at the date of last visit with adequate assessment. For responding patients who receive subsequent anticancer therapy (after discontinuation from the study treatment) prior to progression, duration of response will be censored at the date of last visit with adequate assessment prior to the initiation of post-discontinuation anticancer therapy.

  4. The Number of Participants Who Experienced Adverse Events (AE) [ Time Frame: Through study completion, an average of 1 year ]
    All AE suffered by patients will be recorded and graduated by the NCI CTCAE v1.0.

  5. Overall Survival (OS) [ Time Frame: Through study completion, an average of 1 year ]
    OS was defined as the time elapsed from first treatment until death from any cause.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent.
  • Women older than 18 years old.
  • HER2 positive breast cancer with histological diagnoses.
  • Non-operable locally advanced or metastatic disease, previously treated with trastuzumab and taxanes.
  • Measurable or non-measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST).
  • Disease progression during or after treatment with trastuzumab and taxanes.
  • Maximum of 1 previous chemotherapy line for advanced or metastatic disease.
  • Previous radiotherapy is allowed if radiated area is not the only documented lesion.
  • At least 4 weeks since the last administration of antineoplastic treatment and all toxicities resolved.
  • Performance status Eastern Cooperative Oncology Group (ECOG) >=2.
  • Life expectancy of at least 12 weeks.
  • Left Ventricular Ejection Fraction (LVEF) evaluation (>=50%) in previous 4 weeks.
  • Hematology:

    • neutrophils >=1.5 x 10e9/l;
    • platelets >= 100 x 10e9/l;
    • hemoglobin >= 10 mg/dl
  • Hepatic function:

    • total bilirubin <= 1.5 x under normal limit (UNL);
    • Aspartate aminotransferase (SGOT) and Alanine aminotransferase (SGPT) and alkaline phosphatase <= 2.5 x UNL, or <=5 x UNL if hepatic lesions present
  • Renal function:

    • creatinine <= 175 µmol/l (2 mg/dl);
    • creatinine clearance >= 60 ml/min.
  • Patients able to comply with treatment and follow-up.
  • Negative pregnancy test in the previous 14 days. Adequate contraceptive method during treatment and up to 3 months after finalised.
  • Brain metastatic lesions are allowed provided all other criteria are met.
  • Male who met inclusion criteria are eligible.

Exclusion Criteria:

  • History of hypersensitivity to vinorelbine, trastuzumab, rat proteins or trastuzumab components.
  • History of dyspnea at rest, or chronic oxygen therapy required.
  • Active infection.
  • Second malignancy, except for cervical in situ carcinoma, basal skin carcinoma, adequately treated. Previous malignancies with a 5 year disease free survival are allowed.
  • Pregnant or lactating women.
  • Any other serious medical pathology, such as congestive heart failure, unstable angina, history of myocardial infarction during the previous year, uncontrolled hypertension or high risk arrhythmias.
  • History of neurological or psychiatric disorders, which could preclude the patients to free informed consent.
  • Active uncontrolled infection.
  • Active peptic ulcer, unstable diabetes mellitus.
  • Concomitant treatment with other investigational products. Participation in other clinical trials with a non-marketed drug in the 30 previous days before randomization.
  • Concomitant treatment with other therapy for cancer.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00130507


Locations
Layout table for location information
Spain
Spanish Breast Cancer Research Group (GEICAM)
San Sebastián de los Reyes, Madrid, Spain, 28700
Sponsors and Collaborators
Spanish Breast Cancer Research Group
Hoffmann-La Roche
Investigators
Layout table for investigator information
Study Director: Study Director Hospital Clinic i Provincial

Additional Information:
Layout table for additonal information
Responsible Party: Spanish Breast Cancer Research Group
ClinicalTrials.gov Identifier: NCT00130507     History of Changes
Other Study ID Numbers: GEICAM 2004-06
First Posted: August 15, 2005    Key Record Dates
Last Update Posted: February 26, 2019
Last Verified: February 2019
Keywords provided by Spanish Breast Cancer Research Group:
HER2 positive breast cancer.
Progression to trastuzumab and taxanes.
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Capecitabine
Trastuzumab
Vinorelbine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antineoplastic Agents, Immunological
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators